Cullinan Therapeutics (CGEM, Financial) is set to unveil significant findings from its REZILIENT1 clinical study at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 in Chicago. The study focused on the efficacy of zipalertinib for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who have undergone previous therapies.
The Phase 2b REZILIENT1 trial evaluated zipalertinib as a standalone therapy in individuals with advanced or metastatic EGFR ex20ins NSCLC. These patients had experienced progression following platinum-based chemotherapy, either with or without amivantamab and other therapies targeting ex20ins mutations.
According to Cullinan Therapeutics, findings reveal that zipalertinib demonstrated a notable clinical benefit and maintained a manageable safety profile, even among patients previously treated with amivantamab. This highlights zipalertinib’s potential in addressing the persistent unmet needs faced by this specific patient group, who often have limited treatment options and poor prognoses.
The company expresses enthusiasm in contributing these insights to the lung cancer medical community during its oral presentation at the ASCO conference, aiming to shed light on potential advancements in treatment protocols for this challenging subset of lung cancer patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cullinan Therapeutics Inc (CGEM, Financial) is $32.17 with a high estimate of $35.00 and a low estimate of $29.00. The average target implies an upside of 269.73% from the current price of $8.70. More detailed estimate data can be found on the Cullinan Therapeutics Inc (CGEM) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Cullinan Therapeutics Inc's (CGEM, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
